Deep Dive: AAP Expands Second-Season RSV Protection for High-Risk Children — Background, What Changed, Competing Viewpoints, and What to Watch Next

Deep Dive: AAP Expands Second-Season RSV Protection for High-Risk Children Background Respiratory syncytial virus (RSV) remains a leading cause of hospitalization in young children in the United States, responsible for roughly 58,000 to 80,000 hospitalizations annually in kids under 5. For years, prevention for high-risk infants relied on monthly doses of palivizumab during the season. The 2023–2024 season introduced two major advances: the maternal RSV vaccine (Abrysvo) given in late pregnancy and the long-acting monoclonal antibody nirsevimab (Beyfortus), which provides season-long protection with a single dose. First-season recommendations have been clear: all infants under 8 months entering their first RSV season should receive protection, either through maternal vaccination (at least 14 days before delivery) or infant nirsevimab/clesrovimab. Second-season protection was previously limited to a narrower set of high-risk conditions, primarily chronic lung disease of prematurity requiring recent support, severe immunocompromise, certain cystic fibrosis cases, and American Indian/Alaska Native children. What Changed On September 2, 2026, the American Academy of Pediatrics (AAP) released updated policy recommendations for the 2026–2027 RSV season, accompanied by a detailed technical report published around October 26, 2026, in Pediatrics. The core first-season guidance is unchanged. The significant expansion applies to children aged 8 through 19 months entering their second RSV season. The AAP added four new high-risk groups eligible for a second-season dose of nirsevimab (typically 200 mg): - Children born preterm at less than 32 weeks’ gestation, regardless of whether they still need medication or other support. - Children with hemodynamically significant congenital heart disease (defects that can cause symptoms or enlarge heart chambers). - Children with anatomic pulmonary abnormalities or neuromuscular disorders that increase risk of severe RSV disease. - Children with Down syndrome or other chromosomal differences placing them at higher risk of severe RSV disease. These join the existing criteria. Eligibility is based on chronological age, not corrected age for preterm infants. Protection is recommended regardless of whether the child received maternal vaccine protection or a first-season monoclonal antibody. Clesrovimab is currently indicated only for the first season. The technical report notes that 92% of children requiring ICU-level care for second-season RSV hospitalizations under prior guidelines were ineligible for second-season immunization. Surveillance data showed elevated second-season hospitalization rates in groups such as children with Down syndrome and those born extremely preterm—up to five times the general population’s first-season rate in some analyses. Real-world effectiveness data from recent seasons have shown nirsevimab reducing RSV hospitalizations by roughly 70–90% in eligible populations, with comparable safety profiles for second-season dosing. Competing Viewpoints Pediatric infectious disease experts and the AAP emphasize the clear benefit: these products keep high-risk toddlers out of the hospital, and the expanded criteria capture many children who previously fell through the cracks. Sean T. O’Leary, MD, MPH, FAAP, chair of the AAP’s RSV immunization subgroup, has stated that “the evidence is clear: these products work very well to prevent RSV and keep infants out of the hospital. We’re already seeing real-world impact.” Some clinicians and cost-effectiveness analyses note that second-season protection for broader groups has higher cost per quality-adjusted life year than universal first-season use, given lower absolute risk in the second year. Differences between AAP and CDC high-risk lists have also drawn comment, with the AAP adopting a more expansive approach based on recent hospitalization data. Access and supply remain practical concerns for some families, particularly early in the season. Overall, the professional consensus leans strongly toward offering the protection to the newly included groups rather than waiting for further evidence of harm from under-protection. What to Watch Next Parents of children in the expanded high-risk categories should discuss second-season nirsevimab with their pediatrician as the 2026–2027 RSV season begins (typically October through March in most of the continental U.S.). Watch for: - Local and national RSV activity reports (CDC FluView and state health departments) to time doses optimally. - Any further refinements to high-risk criteria as additional real-world effectiveness data emerge, including studies of the newly expanded groups. - Supply and insurance coverage updates for nirsevimab in the second season. - Ongoing surveillance for rare side effects and for co-circulation with influenza and COVID-19. - Continued uptake of maternal RSV vaccination, which reduces the number of infants needing infant-administered protection. Talk with your child’s clinician about whether your toddler qualifies and how to schedule the dose. The goal is straightforward: fewer hospitalizations and less severe illness for the children at highest risk as they enter their second RSV season. Sources: AAP policy statement and technical report (Pediatrics, 2026); AAP News; CDC data on RSV burden; real-world effectiveness studies presented at IDWeek and PAS meetings.